Fulranumab

Fulranumab is a monoclonal antibody that was under development for the treatment of pain associated with osteoarthritis and diabetic neuropathy. It was designed to bind and inhibit the action of nerve growth factor, a protein that plays a key role in the transmission of pain signals from peripheral tissues to the brain.

Development

Fulranumab was developed by Amgen, a multinational biopharmaceutical company. The development of the drug was discontinued in 2016 due to concerns about side effects and regulatory hurdles. The decision was made despite promising results in early-stage clinical trials.

Mechanism of Action

Fulranumab works by binding to nerve growth factor (NGF), a protein that is involved in the transmission of pain signals. By inhibiting the action of NGF, fulranumab can potentially reduce pain in conditions such as osteoarthritis and diabetic neuropathy.

Clinical Trials

Fulranumab underwent several clinical trials to evaluate its safety and efficacy. The results of these trials showed that the drug was effective in reducing pain in patients with osteoarthritis and diabetic neuropathy. However, the development of the drug was halted due to concerns about side effects and regulatory issues.

Side Effects

The most common side effects of fulranumab include nausea, headache, and peripheral edema. In some cases, the drug can also cause serious side effects such as arthralgia and paresthesia.

See Also

• Monoclonal antibodies
• Nerve growth factor
• Osteoarthritis
• Diabetic neuropathy